High-dose isoniazid for TB with low-to-moderate isoniazid resistance after 1 week of treatment
The utility of high-dose isoniazid against low-level isoniazid resistance beyond the first 2 weeks of chemotherapy should be reconsidered.
Authors
- Bella Devaleenal Daniel (ORCID: https://orcid.org/0000-0001-6293-4990)
- K. Devika
- Ramprasad Srinivasan (ORCID: https://orcid.org/0000-0003-1661-1837)
- K. D. Eisenach
- D Sangamithirai
- Hemachandran Ravikumar (ORCID: https://orcid.org/0000-0003-3548-4327)
- Srikanth Tripathy (ORCID: https://orcid.org/0000-0002-8363-2606)
- Sarah E. Smith-Jeffcoat (ORCID: https://orcid.org/0000-0002-7962-9017)
- J. Peter Cegielski (ORCID: https://orcid.org/0000-0003-2647-4354)
- K Maheswaran
- Lavanya Jayabal
- Santosh Kumar (ORCID: https://orcid.org/0000-0002-3988-868X)
- G Mangalambal
- Rajeswari Sridhar (ORCID: https://orcid.org/0000-0003-1204-1056)
- Dina Nair (ORCID: https://orcid.org/0000-0002-5071-9270)
- M Baskaran
- S. Balaji (ORCID: https://orcid.org/0000-0003-3223-7910)
- Soumya Swaminathan
- G. Radhika
- Uma Devi Ranganathan
Institutions
- Centers for Disease Control and Prevention (US)
- Emory University (US)
- Government Hospital of Thoracic Medicine (IN)
- Indian Council of Medical Research (IN)
Publication Details
- Journal
- JAC-Antimicrobial Resistance
- Published
- 2025-04-29
- DOI
- https://doi.org/10.1093/jacamr/dlaf072
- Primary Topic
- Tuberculosis Research and Epidemiology
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- University of Arkansas for Medical Sciences
- Centers for Disease Control and Prevention